Analysis of 507 patients from 17 Mount Sinai Acute GVHD International Consortium (MAGIC) centers revealed a validated biomarker algorithm, consisting of ST2 and REG3α measured by ELISA, predicting outcomes in steroid resistant GVHD. This evidence concerns the gene REG3A and graft versus host disease.